Charles River Laboratories  

(Public, NYSE:CRL)   Watch this stock  
Find more results for Foster M. Thompson
79.61
+0.60 (0.76%)
Mar 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 78.89 - 80.26
52 week 49.60 - 84.69
Open 79.13
Vol / Avg. 303,677.00/546,981.00
Mkt cap 3.77B
P/E 29.49
Div/yield     -
EPS 2.70
Shares 47.33M
Beta 1.08
Inst. own 98%
Apr 28, 2015
Q1 2015 Charles River Laboratories International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2015
Charles River Laboratories International Inc at Barclays Healthcare Conference - Webcast
Mar 4, 2015
Charles River Laboratories International Inc at Cowen Health Care Conference - Webcast
Mar 3, 2015
Charles River Laboratories International Inc at Raymond James Institutional Investors Conference - Webcast
Feb 12, 2015
Charles River Laboratories International Inc at Leerink Global Healthcare Conference
Feb 11, 2015
Q4 2014 Charles River Laboratories International Inc Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Charles River Laboratories International Inc Earnings Release
Jan 14, 2015
Charles River Laboratories International Inc at JPMorgan Healthcare Conference (Q&A Session)
Jan 14, 2015
Charles River Laboratories International Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 8.66% 10.01%
Operating margin 12.37% 13.69%
EBITD margin - 23.13%
Return on average assets 6.14% 7.39%
Return on average equity 16.75% 19.56%
Employees 7,900 -
CDP Score - -

Address

261 Ballardvale St
WILMINGTON, MA 01887-1039
United States - Map
+1-978-6586000 (Phone)
+1-978-9885665 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Charles River Laboratories International, Inc.is a provider of solutions, which accelerate the early-stage drug discovery and development process. The Company�s portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through RMS segment, the Company supplies research models to the drug development industry. The Company is engaged in the production and sale of rodent research model strains, genetically and microbiologically defined purpose-bred rats and mice. It also provides a range of related services, which are designed to assist its clients in supporting the use of research models in drug discovery and development. The Company�s PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company.

Officers and directors

James C. Foster Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas F. Ackerman Chief Financial Officer, Corporate Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David P. Johst Corporate Executive Vice President, Chief Administrative Officer, General Counsel
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Nancy A. Gillett Ph.D. Chief Scientific Officer, Corporate Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Geoff Goldsmith Corporate Executive Vice President, Global Productivity and Efficiency
Bio & Compensation  - Reuters
Davide A. Molho Corporate Executive Vice President ; President, Global Research Models & Services and Preclinical Services Operations
Age: 45
Bio & Compensation  - Reuters
George M. Milne Jr., Ph.D. Lead Independent Director
Bio & Compensation  - Reuters
Craig B. Thompson M.D. Director
Age: 47
Bio & Compensation  - Reuters
Robert E. Bertolini CPA Independent Director
Age: 53
Bio & Compensation  - Reuters
Stephen D. Chubb Independent Director
Age: 70
Bio & Compensation  - Reuters